Oncolytics Biotech
ONCY
59 hedge funds and large institutions have $3.34M invested in Oncolytics Biotech in 2026 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 17 increasing their positions, 3 reducing their positions, and 16 closing their positions.
467% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 3
36% more capital invested
Capital invested by funds: $2.45M → $3.34M (+$887K)
1.06% more ownership
Funds ownership: 2.79% → 3.84% (+1.1%)
6% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 16
3% less funds holding
Funds holding: 61 → 59 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$712K |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$594K |
| 3 |
SFP
Sandbox Financial Partners
Bethesda,
Maryland
|
+$398K |
| 4 |
EFG
Everhart Financial Group
Dublin,
Ohio
|
+$137K |
| 5 |
DA
Doliver Advisors
Houston,
Texas
|
+$99.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$396K |
| 2 |
IAIM
International Assets Investment Management
Orlando,
Florida
|
-$182K |
| 3 |
Goldman Sachs
New York
|
-$148K |
| 4 |
CCM
Connective Capital Management
Palo Alto,
California
|
-$131K |
| 5 |
VF
Virtu Financial
New York
|
-$68K |
ONCY Hedge Fund Activity: Q1 2026 in Review
59 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in Oncolytics Biotech (ONCY) for Q1 2026, worth a combined $3.34M — up 36% from $2.45M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of ONCY and 15 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 17 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $712K. The largest seller was Morgan Stanley, cutting an estimated $396K.
- 59 institutional investors held Oncolytics Biotech (ONCY) as of Q1 2026, down from 61 in Q4 2025.
- Funds reported $3.34M of Oncolytics Biotech stock for Q1 2026, up 36% quarter-over-quarter.
- 15 funds opened new Oncolytics Biotech positions in Q1 2026 and 16 closed out, a net change of -1 holder.
- The largest Oncolytics Biotech buyer in Q1 2026 was Renaissance Technologies, an estimated $712K added.
- The largest Oncolytics Biotech seller in Q1 2026 was Morgan Stanley, an estimated $396K sold.
Based on aggregated 13F filings for Q1 2026.